Biolegend, 135216, PE/Cyanine7 anti-mouse CD279 (PD-1) Antibody, 100μg

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration: 0.2 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
Application References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed Read KA, et al. 2023. Nat Commun. 14:1652. PubMed Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed Liu J, et al. 2021. Front Immunol. 12:747730. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Dölz M, et al. 2022. iScience. 25:105372. PubMed Edwards SC, et al. 2023. J Exp Med. 220: . PubMed Yeh CH, et al. 2022. Immunity. 55:272. PubMed Aggen DH, et al. 2020. Clin Cancer Res. . PubMed Wang L, et al. 2019. Cell Rep. 29:1848. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Shi B, et al. 2018. J Immunol. 200:586. PubMed Wei H, et al. 2021. Malar J. 20:89. PubMed Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Browning LM, et al. 2020. Cell Rep. 33:108219. PubMed Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed Wiede F, et al. 2021. Cancer Discov. Online ahead of print. PubMed Saumyaa, et al. 2016. J Immunol. 196: 3677 - 3685. PubMed Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed Saumyaa S, et al. 2013. Infect Immun . 81:3426. PubMed Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed Yue X, et al. 2019. Nat Commun. 10:2011. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed Watanabe M, et al. 2020. Nat Commun. 4.808333333. PubMed Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed Ullrich L, et al. 2021. Front Immunol. 12:729607. PubMed Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed Blanchard L, et al. 2022. STAR Protoc. 3:101444. PubMed Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed Dong X, et al. 2022. Front Immunol. 13:896472. PubMed Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed Zeis P, et al. 2020. Immunity. 53:775. PubMed Burton B, et al. 2014. Nat Commun. 5:4741. PubMed Yermanos A, et al. 2020. Front Immunol. 1.143055556. PubMed Skadow M, et al. 2019. J Immunol. 203:370. PubMed Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed Tian D, et al. 2019. Nat Commun. 10:4246. PubMed Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed Sheriff L, et al. 2022. STAR Protoc. 11:. PubMed NB M, et al. 2017. J Immunol. 198:1142-1155. PubMed Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed Liang Z, et al. 2022. iScience. 25:105233. PubMed Trindade BC, et al. 2021. Immunity. 54:2273. PubMed Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
RRID: AB_10696422 (BioLegend Cat. No. 135215) AB_10689635 (BioLegend Cat. No. 135216)
Structure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, T cells
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313
Gene ID: 18566
UniProt: View information about CD279 on UniProt.org
Clone: 29F.1A12
Regulatory Status: RUO
Other Names: PD-1, Programmed Death-1, PDCD1
Isotype: Rat IgG2a, κ